Medicines Discovery Catapult welcomes UK Government’s long-term investment in life sciences innovation





In response to the UK Government’s Budget 2020 , Chris Molloy, CEO of the Medicines Discovery Catapult said:

“Today’s budget announced £200M in funding directly targeted at the life sciences, and dramatically increased scientific research funding, providing more breakthroughs that we can help our sector turn into commercial products. Medicines Discovery Catapult is testament to the Government’s broad ambition to ensure the UK remains a world leader in life sciences research and innovation. I welcome it and the potential it creates.

“The UK is a global hub for biotech and the generation of new medicines. Our tools, skills and network support the UK sector’s mission to create valuable new treatments for patients.  This boost to our national reserves of IP and focussed finance is enabling.

“As a national centre based in the North West, working across all regions, I also welcome the additional £400M in funding for science and technology right across the UK. It will help us to turn more of the whole nation’s great science into new world-class products and services.

“I also welcome the formation of a new blue-skies funding agency. Pioneering with purpose into new areas requires ambition and agility. I look forward to seeing the new agency use this initial £800M to give big new ideas the fuel they need to succeed.”







Other News

new board appointments
News
15 September 2026
Medicines Discovery Catapult appoints global life science and commercialisation leaders to its Board of Directors

New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.


News
10 September 2026
Inspiring the next generation: Medicines Discovery Catapult scientist contributes to children’s science book 

Dr Emma Jones, a Lead Scientist in in vitro Neurobiology at Medicines Discovery Catapult (MDC), has contributed to a new children’s book celebrating the diversity of careers in science.


News
03 September 2026
Medicines Discovery Catapult invests in UK biotech pioneers developing novel treatments for chronic diseases

Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.





Medicines Discovery Catapult